US Personalized Cancer Genome Sequencing Market Outlook 2018 –

US Personalized Cancer Genome Sequencing Market Outlook 2018

Reporter: Aviva lev-Ari, PhD, RN

Published: March 2014 | Pages: 65 | Format: PDF

The whole genome sequencing technology, over the past decade, has developed at an unprecedented rate. There has been a rapid progression from targeted gene sequencing to targeted whole genome sequencing coupled with bioinformatics based sequencing platforms to analyze the data and thereby impart personalized treatment to individuals. The Whole Genome Sequencing has proved to be a key to new breakthrough in fighting against cancer. The explosion of genomic data into personalized treatment of cancer is due to the development of new methods, and the exponential decline in cost of whole genome sequencing.

Our report entitled “US Personalized Cancer Genome Sequencing Market Outlook 2018” entails detailed study of current and future cancer prevalence and incidences across US. In addition, it provides an insight about the leading states with cancer incidences. Also covered is age wise statistics for cancer and comprehensive figures for cancer in males and females. Further, we have provided potential states for whole genome sequencing to help market players gauge maximum opportunity for growth. Besides, the report also provides potential customer base and the market’s growth potential for personalized cancer WGS till 2018.

The said advanced technology has potential to revolutionize the field of medicine. We have closely monitored the regulatory landscape related to sequencing which requires consideration of the authorities over genome based tests. It has been observed that whole genome sequencing services have been concurrently regulated by FDA, CDC and CMS. Further, we have also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. Apart from this, a major hurdle is to persuade health insurers to reimburse for the cost of sequencing the genomes of individual.

The report analyzes the competitive landscape of the market by properly analyzing the business, services and activities of the companies such as Illumina, Complete Genomics, and Ambry Genetics. It also provides the competitive benchmarking, taking into account key information such as market value, revenues, risk score etc., along with the strengths and weaknesses of each player. Overall, the report is a complete source of knowledge and statistics for clients who want to get an in-depth understanding of the market.